Skip to main content
OpenTrials
Completed

NCT Number: NCT01361191

Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

The aim of the study is to evaluate the event free survival at three years in patients with diffuse large B-cell lymphoma with poor prognostic factors receiving R-MegaCHOP as induction therapy. Patients with positive PET after three cycles of R-MegaCHOP receive early salvage treatment with R-IFE and autologous stem cell transplantation. Patients with negative PET after three cycles of R-MegaCHOP are treated with three additional cycles of R-MegaCHOP without transplant.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diffuse Large B-cell Lymphoma Follicular Grade 3B Lymphoma Hemic and Lymphatic Diseases Immune System Diseases Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

ICO- Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain

Loading trial locations.

About this study

In addition to the above:

  • To evaluate the overall survival after three years.
  • To determine the rate of global responses and complete remissions, uncertain and partial.
  • To determine the duration of the complete response after the treatment termination.
  • To carry out an exploratory follow up of the event free survival and the overall survival at 5 years.
  • To evaluate the treatment toxicity according CTC criteria (version 3.0) of the National Cancer Institute (NCI).
  • To asses the role of PET in the disease stage and response evaluation compared to CAT.
  • To identify the predictable response factors after 6 cycles of treatment with R-MegaCHOP administrated every 21 days; or 3 cycles of R-MegaCHOP, followed by IFE+TAPH in patients with DLBCL of severe prognosis.
  • To evaluate the therapeutic fulfillment of the R-MegaCHOP and R+IFE cycles of treatment and/or R-IFE in reference with delays with the cycles administration and reductions of the chemotherapy dose (planned dose administrated in the planned term).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • follicular lymphoma grade III diagnosed patients, diffuse large B-cell lymphoma, histologically confirmed with CD20+
  • aged between 18 and 65 years. Patients aged from 65 to 70 years can be included according to the investigator's criteria regarding the patients' global health status and the absence of excluding comorbidity.
  • IPI adjusted to the age over 1 or a-IPI and beta2-microglobulin equal or higher than 3 mg/dl 3. Punctuation in the ECOG grade from 0 to 4
  • Life expectancy over 12 weeks
  • Written informed consent form 6. New diagnosed patient without any previous treatment

Exclusion criteria

  • Existence of severe cardiac, pulmonary, neurologic, psychiatric and metabolic diseases not caused by the lymphoma.
  • uncontrolled high blood pressure (diastolic pressure in rest > 115 mmHg)
  • Altered hepatic function (bilirubin or AST/ALT superior or equal at 2 times the superior limit of normality) or renal (creatinine equal or superior at 1.5 times the superior limit of normality) not caused by the lymphoma.
  • other malignant neoplasias along the past 5 years, except skin tumors, excluded melanoma or carcinoma in situ of cervix
  • patients positive for HIV
  • patients with transformed follicular lymphoma
  • pregnant women or in nursing; women of childbearing age who do not use an adequate contraceptive method before being included in the study
  • ventricular ejection fraction inferior to 50%
  • patients with severe psychiatric diseases which can interfere with their ability for understanding the study (including alcoholism or drug addiction)

Treatment and study plan

R-MEGACHOP

Drug
  • If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT
  • If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5

R-IFE: 2 cycles every 21 days:

IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.

ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3).

Primary outcomes

  1. Event free survival at 3y in pat with DLBCL with a-IPI>1 or a-IPI=1 and ß2 µglobulin>=3mg/dl in pat PET+ after 3cycles of R-MegaCHOP and early rescue with R-IFE+TAPH or in pat PET- after 3cycles R-MegaCHOP followed by 3cycles of R-MegaCHOP without TAPH

    Time frame: 5 years follow-up

Secondary outcomes

  1. To evaluate the overall survival after three years. Further secondary outcomes as described in study summary.

    Time frame: 5 years follow-up

Sponsors and collaborators

Lead sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Other

Registry information

Official study title

Early Treatment Stratification Based on PET Scan Response to R-MEGACHOP Followed by R-MEGACHOP or R-IFE Plus Peripheral Autologous Stem Cell Transplant (PBSCT) in Patients With Poor Prognosis DLBCL

Acronym: R-MEGACHOP

Important dates

Study start
2007
Primary completion
2012
Study completion
2012
First posted
May 26, 2011
Registry last updated
Oct 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.